Case report and literature analysis of Mycobacterium iranicum infection
- VernacularTitle:伊朗分枝杆菌感染的案例报道及文献分析
- Author:
Yewen ZHANG
1
,
2
;
Chengling LUO
3
;
Wengao JIANG
1
;
Min CHEN
3
;
Qian DU
4
;
Wei YAO
3
;
Songqing LIU
4
;
Xin XI
4
Author Information
1. College of Pharmacy，Chongqing Medical University，Chongqing 401120，China
2. School of Basic Medicine and Clinical Pharmacy，China Pharmaceutical University，Nanjing 210000，China
3. Dept. of Respiratory Medicine，Third Affiliated Hospital of Chongqing Medical University，Chongqing 401120，China
4. Dept. of Pharmacy，Third Affiliated Hospital of Chongqing Medical University，Chongqing 401120，China
- Publication Type:Journal Article
- Keywords:
Mycobacterium iranicum;
nontuberculous
- From:
China Pharmacy
2025;36(15):1931-1935
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To offer a reference for the treatment of Mycobacterium iranicum infection by analyzing the diagnosis and management of a single case alongside literature-reported cases. METHODS Through case report and literature reviews， this study synthesized the clinical features， therapeutic regimens， and patient outcomes of those infected with M. iranicum. RESULTS In the single case documented in this report， subsequent to clinical pharmacists’ involvement in the consultation， the patient was prescribed a therapeutic regimen comprising levofloxacin （0.5 g， qd， ivgtt）+Clarithromycin sustained-release tablets （1 000 mg， qd， po） + Ethambutol tablets （0.75 g， qd， po）. The patient exhibited clinical improvement and was discharged after treatment. This article integrated 12 published studies， encompassing 13 patients （7 male and 6 female）， of whom 69.23% were aged ≥50 years. Patients infected with M. iranicum exhibited non-specific clinical manifestations and imaging features， with pulmonary infection as the primary presentation. Antimicrobial susceptibility test revealed that M. iranicum was susceptible to multiple agents， including amikacin， clarithromycin， linezolid， and ethambutol. The three-drug combination therapy was the most frequently employed regimen. In terms of clinical outcomes， there were 9 cases （69.23%） of clinical cure， 3 cases （23.08%） of bacteriological negativity conversion， and 1 case （7.69%） of treatment failure. CONCLUSIONS For M. iranicum infection， a triple-drug therapeutic regimen consisting of three agents with distinct mechanisms of action selected from amikacin， clarithromycin， moxifloxacin， levofloxacin， minocycline， ethambutol， and other relevant drugs may represent a relatively optimal strategy.
